Instrucciones de búsqueda:
* Filter the ENTIRE resource library: Choose a OR a to sort all resources.
* Choose Search Items : to filter one collection or perform complex queries.
* Choose Browse by Topic to search by one or more Topics.
Navegar por los elementos (1475 total)
-
Autor: the ENSEMBLE Study Group
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-06-10
Descripción: The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in a prefusion-stabilized conformation. -
Autor: the COVID-19 Genomics UK (COG-UK) consortium
Tema: Personnel Management
Tipo de elemento: Publicación
Fecha de actualización: 2021-08-27
Descripción: The SARS-CoV-2 delta (B.1.617.2) variant was first detected in England in March, 2021. It has since rapidly become the predominant lineage, owing to high transmissibility. It is suspected that the delta variant is associated with more severe disease…Example only: NETEC provides this item for reference purposes but does not endorse its content. Newer versions may be in place at the providing institution.
-
Autor: the COVE Study Group
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-02-04
Descripción: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle–encapsulated mRNA-based vaccine that encodes the prefusion stabilized… -
Autor: the BLAZE-1 Investigators
Tema: Treatment & Care
Tipo de elemento: Publicación
Fecha de actualización: 2021-10-07
Descripción: Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive immunity and… -
Autor: the BATS Consortium
Tema: Treatment & Care
Tipo de elemento: Publicación
Fecha de actualización: 2021-06-16
Descripción: Evidence is urgently needed to support treatment decisions for children with multisystem inflammatory syndrome (MIS-C) associated with severe acute respiratory syndrome coronavirus 2.Example only: NETEC provides this item for reference purposes but does not endorse its content. Newer versions may be in place at the providing institution.
-
Autor: The Association for Professionals in Infection Control and Epidemiology (APIC)
Tema: Infection Control
Tipo de elemento: Guía
Fecha de actualización: 2023
Descripción: This 2013 Infection Control Risk Assessment( Example Template) can be viewed alongside the APIC Risk Assessment Template. -
Autor: The Association for Professionals in Infection Control and Epidemiology (APIC)
Tema: Infection Control
Tipo de elemento: Guía
Fecha de actualización: 2023
Descripción: This Risk Assessment tool can be used to conduct a facility risk assessment for acquiring and transmitting infections in a variety of ambulatory healthcare settings. The results of the risk assessment can then be reported using the accompanying… -
Autor: the Ambulatory COVID Study Team
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-01-05
Descripción: Outpatient coronavirus disease 2019 (COVID-19) has been insufficiently characterized. To determine the progression of disease and determinants of hospitalization, we conducted a prospective cohort study. -
Autor: the ACTT-1 Study Group Members
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2020-11-05
Descripción: We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.A response to this article was published:Dolin, Raphael,… -
Autor: the ACTT-1 Study Group Members
Tema: Treatment & Care
Tipo de elemento: Publicación
Fecha de actualización: 2020-05-22
Descripción: Discussing "a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement."
